Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai
Reexamination Certificate
2007-08-14
2007-08-14
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ketone doai
C514S685000, C568S327000, C568S334000, C549S049000, C549S379000, C549S505000, C546S112000, C548S469000, C548S565000
Reexamination Certificate
active
10471720
ABSTRACT:
The present invention is directed to multifluoro-substituted Chalcones and analogs thereof, represented by the general Formula I:wherein Ar and R6-R10are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 5144029 (1992-09-01), Ward et al.
patent: 5739163 (1998-04-01), Cain et al.
patent: WO99/18856 (1999-04-01), None
Howell, A. Overview of the impact of conventional systemic therapies on breast cancer (2005) Endocrine-Related Cancer 12: S9-S16.
Heenen, M., et al., “Methotrexate induces apoptotic cell death in human keratinocytes,”Arch. Dermatol. Res. 290:240-245, Springer-Verlag (1998).
Infante, A.J., et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr. 133:629-633, Mosby, Inc. (1998).
Leu, Y.-L., et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT),”J. Med. Chem. 42:3623-3628, American Chemical Society (1999).
López-Hoyos, M., et al., “Regulation of B Cell apoptosis by Bcl-2 and Bcl-XLand its role in the development of autoimmune diseases (Review),”Int. J. Mol. Med. 1:475-483, D.A. Spandidos (1998).
Los, M., et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood 90:3118-3129, W. B. Saunders (1997).
Ohsako, S., and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Stockton Press (1999).
O'Reilly, L.A., and Strasser, A., “Apoptosis and aútoimmune disease,”Inflamm. Res. 48:5-21, Birkhäuser Verlag (1999).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med. 189:711-718, The Rockefeller University Press (1999).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leukoc. Biol. 61:375-380, The Society for Leukocyte Biology (1997).
Schmitt, E., et al., “The Bcl-xL and Bax-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation,”Biochem. Cell Biol. 75:301-314, National Research Council of Canada (1997).
Tai, D-I., et al., “Activation of Nuclear Factor κB in Hepatits C Virus Infection: Implications for Pathogenesis and Hepatocarcinogenesis,”Hepatology 31:656-664, W.B. Saunders Co. (Mar. 2000).
Vaishnaw, A.K., et al., “The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations,”J. Clin. Invest. 103:355-363, The American Society for Clinical Investigation (1999).
Wakisaka, S., et al., “Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA),”Clin. Exp. Immunol. 114:119-128, Blackwell Science (1998).
Zhou, T., et al., “Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases,”Nat. Med. 5:42-48, Nature Publishing Co. (1999).
International Search Report for International Application No. PCT/US02/07569, 3 pages, ISA.US, Commissioner of Patents and Trademarks, Washington, D.C. (mailed Sep. 25, 2002).
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, American Association of Immunologists (1999).
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroenterology 116:557-565, W.B. Saunders (1999).
Chinnaiyan, A.M., et al., “The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication,”Nat. Med. 3:333-337, Nature Pub. Co. (1997).
Coven, T.R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Blackwell Munksgaard (1999).
Friesen, C., et al., “Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nat. Med. 2:574-577, Nature Pub. Co. (1996).
Greenwald, R.B., et al., “Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds,”J. Med. Chem. 42:3657-3667, American Chemical Society (1999).
Chabner, B.A., et al., “Antineoplastic Agents” inGoodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, Chapter 51, Hardman, J.G., et al., eds., McGraw-Hill, New York, NY, pp. 1233-1287 (1996).
Los, M., et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood 90:3118-3129, American .Society of Hematology (1997).
Ohsako, S., and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Nature Pub. Co. (1999).
O'Reilly, L.A., and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. Res. 48:5-21, Birkhäuser (1999).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leukoc. Biol. 61:375-380, Federation of American Societies for Experimental Biology (1997).
Tai, D-I., et al., “Activation of Nuclear Factor κB in Hepatitis C Virus Infection: Implications for Pathogenesis and Hepatocarcinogenesis,”Hepatology 31:656-664, W.B. Saunders (2000).
Wakisaka, S., et al., “Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA),”Clin. Exp. Immunol. 114:119-128, Blackwell Scientific Publications (1998).
Zhou, T., et al., “Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T Cell-mediated autoimmune diseases,”Nat. Med. 5:42-48, Nature Pub. Co. (1999).
International Search Report for PCT Application No. PCT/US02/07569, mailed Sep. 25, 2002, 2 pages, United States International Searching Authority, Washington, DC.
Cai Sui Xiong
Drewe John A.
Kasibhatla Shailaja
Nguyen Bao Ngoc
Reddy P. Sanjeeva
Claytor Renee
Cytovia, Inc.
Padmanabhan Sreeni
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Multifluoro-substituted chalcones and analogs as activators... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multifluoro-substituted chalcones and analogs as activators..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multifluoro-substituted chalcones and analogs as activators... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3859514